The ASCO Post

The HER2-positive breast cancer treatment landscape continues to advance through innovative combination approaches.

New findings from a Chinese study suggest that dual HER2-targeted strategies may further improve response rates in patients with locally advanced disease, supporting ongoing efforts to optimize neoadjuvant treatment.

Presented by Chenghui Yang, PhD at

https://ascopost.com/news/june-2026/chinese-study-of-her2-targeted-combination-therapy-for-locally-advanced-breast-cancer/

: AI-driven proteomics may open new possibilities for lung cancer prevention.

An international team identified a plasma protein signature associated with future lung cancer risk more than 5 years before diagnosis.

Key findings:
• 14-protein signature identified through machine learning
• Improved prediction compared with current risk models
• Links between inflammation, environmental exposure, and future cancer risk
• Potential pathway toward targeted prevention strategies

https://ascoai.org/articles/2026/06/machine-learning-derived-plasma-protein-signature-may-enable-lung-cancer-prediction-years-before-diagnosis/

Ten-year follow-up data from the FAST-Forward trial continue to support a shorter approach to breast cancer radiotherapy.

Researchers reported that a 1-week adjuvant radiotherapy schedule maintained low rates of local recurrence and demonstrated comparable long-term outcomes to the traditional 3-week regimen.

Findings support both clinical effectiveness and patient-centered care.

Led by Adrian Murray Brunt, FRCR of The Institute of Cancer Research; Published in The Lancet Oncology

https://ascopost.com/news/june-2026/long-term-outcomes-of-adjuvant-hypofractionated-radiotherapy-for-breast-cancer